Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$22.54 USD

22.54
902,104

-0.40 (-1.74%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $22.67 +0.13 (0.58%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's What Key Metrics Tell Us About Pacira (PCRX) Q2 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Pacira (PCRX) Tops Q2 Earnings Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of +2.78% and -1.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is the Options Market Predicting a Spike in Pacira BioSciences Stock?

by Zacks Equity Research

Investors need to pay close attention to PCRX stock based on the movements in the options market lately.

Zacks Equity Research

Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth.

Zacks Equity Research

Pacira (PCRX) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Pacira (PCRX) Q1 Earnings Surpass Estimates

by Zacks Equity Research

Pacira (PCRX) delivered earnings and revenue surprises of 8.77% and 3.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of -11.76% and 14.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Ahan Chakraborty headshot

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates

by Ahan Chakraborty

Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.

Zacks Equity Research

Amgen (AMGN) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Amgen (AMGN) delivered earnings and revenue surprises of 17.79% and 2.47%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

ImmunityBio (IBRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock?

by Zacks Equity Research

Growth across the R&DS and TAS segments is anticipated to have boosted IQV's top line in the first quarter of 2025.

Zacks Equity Research

Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why Pacira (PCRX) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb

by Zacks Equity Research

Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.

Ekta Bagri headshot

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

by Ekta Bagri

PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news.

Zacks Equity Research

Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Pacira (PCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

PCRX Stock Soars on Exparel Patent Settlement With Generic Players

by Zacks Equity Research

Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.

Zacks Equity Research

Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report?

by Zacks Equity Research

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study

by Zacks Equity Research

Pacira doses the first patient in the phase II ASCEND study of PCRX-201 gene therapy for OA of the knee.

Ekta Bagri headshot

Pacira Surges 66.8% in Six Months: How Should You Play the Stock?

by Ekta Bagri

PCRX has put up a strong performance in six months with shares rallying 66.8%. However, its sole dependence on Exparel for growth is a concern. We advise investors to wait for now.

Shaun Pruitt headshot

3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX,

by Shaun Pruitt

These highly ranked medical stocks have the value and essential services that investors may be looking for as tariff concerns and geopolitical tensions have started to rattle markets.

Zacks Equity Research

FDA Accepts RHHBY's sNDA for Gazyva in Treating Lupus Nephritis

by Zacks Equity Research

Roche's filing is based on data from a late-stage study that shows a complete renal response benefit in lupus nephritis patients who received Gazyva.

Zacks Equity Research

ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y

by Zacks Equity Research

Esperion reports a narrower-than-expected loss for the fourth quarter of 2024. Revenues lag estimates. Stock up.

Zacks Equity Research

Pacira BioSciences and Golden Entertainment in the Box have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Pacira BioSciences and Golden Entertainment in the Box have been highlighted as Zacks Bull and Bear of the Day

David Bartosiak headshot

Bull of the Day: Pacira BioSciences (PCRX)

by David Bartosiak

Earnings moving in the right direction and a bounce off technical support sets this stop up nicely.